These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 37180412)

  • 1. What are the benefits of the anti-FGF23 antibody burosumab on the manifestations of X-linked hypophosphatemia in adults in comparison with conventional therapy? A review.
    Lafage-Proust MH
    Ther Adv Rare Dis; 2022; 3():26330040221074702. PubMed ID: 37180412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis.
    Insogna KL; Briot K; Imel EA; Kamenický P; Ruppe MD; Portale AA; Weber T; Pitukcheewanont P; Cheong HI; Jan de Beur S; Imanishi Y; Ito N; Lachmann RH; Tanaka H; Perwad F; Zhang L; Chen CY; Theodore-Oklota C; Mealiffe M; San Martin J; Carpenter TO;
    J Bone Miner Res; 2018 Aug; 33(8):1383-1393. PubMed ID: 29947083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of burosumab in improving phosphate metabolism, bone health, and quality of life in adolescents with X-linked hypophosphatemic rickets.
    Baroncelli GI; Grandone A; Aversa A; Sessa MR; Pelosini C; Michelucci A; Toschi B; Manca M; Isola A; Comberiati P
    Eur J Med Genet; 2024 Aug; 70():104958. PubMed ID: 38950880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone Matrix Mineralization and Response to Burosumab in Adult Patients With X-Linked Hypophosphatemia: Results From the Phase 3, Single-Arm International Trial.
    Fratzl-Zelman N; Hartmann MA; Gamsjaeger S; Rokidi S; Paschalis EP; Blouin S; Zwerina J
    J Bone Miner Res; 2022 Sep; 37(9):1665-1678. PubMed ID: 35775373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. X-linked hypophosphatemia and burosumab: Practical clinical points from the French experience.
    Bacchetta J; Rothenbuhler A; Gueorguieva I; Kamenicky P; Salles JP; Briot K; Linglart A
    Joint Bone Spine; 2021 Oct; 88(5):105208. PubMed ID: 34102329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Burosumab for Pediatric X-Linked Hypophosphatemia.
    Imel EA
    Curr Osteoporos Rep; 2021 Jun; 19(3):271-277. PubMed ID: 33970403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period.
    Portale AA; Carpenter TO; Brandi ML; Briot K; Cheong HI; Cohen-Solal M; Crowley R; Jan De Beur S; Eastell R; Imanishi Y; Imel EA; Ing S; Ito N; Javaid M; Kamenicky P; Keen R; Kubota T; Lachmann R; Perwad F; Pitukcheewanont P; Ralston SH; Takeuchi Y; Tanaka H; Weber TJ; Yoo HW; Zhang L; Theodore-Oklota C; Mealiffe M; San Martin J; Insogna K
    Calcif Tissue Int; 2019 Sep; 105(3):271-284. PubMed ID: 31165191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis and management of X-linked hypophosphatemia in children and adolescent in the Gulf Cooperation Council countries.
    Al Juraibah F; Al Amiri E; Al Dubayee M; Al Jubeh J; Al Kandari H; Al Sagheir A; Al Shaikh A; Beshyah SA; Deeb A; Habeb A; Mustafa M; Zidan H; Mughal MZ
    Arch Osteoporos; 2021 Mar; 16(1):52. PubMed ID: 33660084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Burosumab Improved Histomorphometric Measures of Osteomalacia in Adults with X-Linked Hypophosphatemia: A Phase 3, Single-Arm, International Trial.
    Insogna KL; Rauch F; Kamenický P; Ito N; Kubota T; Nakamura A; Zhang L; Mealiffe M; San Martin J; Portale AA
    J Bone Miner Res; 2019 Dec; 34(12):2183-2191. PubMed ID: 31369697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia.
    Linglart A; Imel EA; Whyte MP; Portale AA; Högler W; Boot AM; Padidela R; Van't Hoff W; Gottesman GS; Chen A; Skrinar A; Scott Roberts M; Carpenter TO
    J Clin Endocrinol Metab; 2022 Feb; 107(3):813-824. PubMed ID: 34636899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world data of Brazilian adults with X-linked hypophosphatemia (XLH) treated with burosumab and comparison with other worldwide cohorts.
    Vaisbich MH; de Cillo ACP; Silva BCC; DÁlva CB; de Carvalho ÉH; de Almeida JMCM; Marques LLM; Ribeiro M; da Silva MBM; de Medeiros PFV; Mendes PH
    Mol Genet Genomic Med; 2024 Feb; 12(2):e2387. PubMed ID: 38337160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphatonins: From Discovery to Therapeutics.
    Kritmetapak K; Kumar R
    Endocr Pract; 2023 Jan; 29(1):69-79. PubMed ID: 36210014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disease Manifestations and Complications in Dutch X-Linked Hypophosphatemia Patients.
    Bosman A; Appelman-Dijkstra NM; Boot AM; de Borst MH; van de Ven AC; de Jongh RT; Bökenkamp A; van den Bergh JP; van der Eerden BCJ; Zillikens MC
    Calcif Tissue Int; 2024 Mar; 114(3):255-266. PubMed ID: 38226986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Burosumab Treatment on Two Siblings with X-Linked Hypophosphatemia. Case Report and Literature Review.
    Jurca CM; Iuhas O; Kozma K; Petchesi CD; Zaha DC; Bembea M; Jurca S; Paul C; Jurca AD
    Genes (Basel); 2022 Aug; 13(8):. PubMed ID: 36011303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. X-linked hypophosphatemic rickets and nephrocalcinosis: clinical characteristics of a single-center pediatric cohort in North America before and after burosumab.
    Paloian NJ; Boyke-Lohmann LR; Steiner RD
    Front Pediatr; 2024; 12():1430921. PubMed ID: 39156019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nephrocalcinosis and kidney function in children and adults with X-linked hypophosphatemia: baseline results from a large longitudinal study.
    Portale AA; Ward L; Dahir K; Florenzano P; Ing SW; Jan de Beur SM; Martin RM; Meza-Martinez AI; Paloian N; Ashraf A; Dixon BP; Khan A; Langman C; Chen A; Wang C; Roberts MS; Tandon PK; Bedrosian C; Imel EA
    J Bone Miner Res; 2024 Sep; 39(10):1493-1502. PubMed ID: 39151033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. X-Linked Hypophosphatemia: A New Era in Management.
    Dahir K; Roberts MS; Krolczyk S; Simmons JH
    J Endocr Soc; 2020 Dec; 4(12):bvaa151. PubMed ID: 33204932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A case report to assess the safety and efficacy of Burosumab, an investigational antibody to FGF23, in a single pediatric patient with Epidermal Nevus Syndrome and associated hypophosphatemic rickets.
    Huynh C; Gillis A; Fazendin J; Abdullatif H
    Bone Rep; 2022 Dec; 17():101605. PubMed ID: 35899095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Burosumab and Dental Abscesses in Children With X-Linked Hypophosphatemia.
    Gadion M; Hervé A; Herrou J; Rothenbuhler A; Smail-Faugeron V; Courson F; Linglart A; Chaussain C; Biosse Duplan M
    JBMR Plus; 2022 Nov; 6(11):e10672. PubMed ID: 36398111
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.